Atopic Dermatitis

The results from this 5-year, open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, describes different methods dermatologists can use to treat atopic dermatitis (AD).

Because of their study's findings, the researchers urged clinicians to screen patients with atopic dermatitis (AD) for cognitive dysfunction.

April Armstrong, MD, MPH, of University of California, Los Angeles, discussed how recent biologics advancements improved moderate-to-severe atopic dermatitis (AD) treatment.

The most common conditions or concerns patients with atopic dermatitis (AD) reported having that may influence their selection of a JAK inhibitor included an increased risk of MACE and an age above 65 years.

April Armstrong, MD, MPH, of University of California, Los Angeles, gave an overview of her Fall Clinical Dermatology session on treating atopic dermatitis (AD) in patients with diverse skin tones and weighed in on how to address related treatment barriers.

April Armstrong, MD, MPH, of University of California, Los Angeles, explained that the main health care gap within the atopic dermatitis (AD) realm is that many clinicians are not comfortable prescribing systemic medications.

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.

The researchers explained that little is known about how primary care providers should handle atopic dermatitis (AD) cases and whether they should follow national recommendations.

These findings support the importance of children with atopic dermatitis (AD) receiving patch testing to consider allergic contact dermatitis as a comorbidity.

Researchers found that EczemaNet2 was more accurate and robust in terms of atopic dermatitis (AD) detection than its predecessor, EczemaNet1.

Natural and synthetic antimicrobial peptides can penetrate deeper skin layers.

Investigators found a steady reduction of immunoglobulin E (IgE) levels in patients regardless of dupilumab dosing interval.

According to researchers, only 3 studies have previously explored a potential link between AD and dementia with inconsistent findings.

As patients’ atopic dermatitis (AD) worsens, the risk of inflammatory bowel disease, Crohn disease, and ulcerative colitis increases.

After treatment, the mental health and sleep quality of mothers in the mild atopic dermatitis (AD) group improved significantly, while those of mothers in the moderate and severe AD groups only showed some improvement.

The researchers’ findings suggest an increased prevalence of mental illness in people with eczema and psoriasis, but they found poor agreement in disease ascertainment settings.

The study comprehensively described the atopic dermatitis (AD) burden among young Japanese patients with moderate or severe forms of the disease.

Researchers found that infections and antibiotic use appear to affect the development of late-onset atopic dermatitis (AD), with respiratory infections having a particularly strong influence.

Patients given LNK01001 showed significant improvement in Eczema Area and Severity Index scores over placebo.

Researchers found that 2.4% of the adult UK population had active atopic dermatitis (AD) between 2015 and 2019, the majority of which were mild cases of AD, as only 7.5% to 8.3% of the population had moderate to severe AD.

This review verified past study findings, finding that probiotics can effectively improve atopic dermatitis (AD) in children.

Researchers found that treatment for atopic dermatitis could contribute to a higher mutation rate.

Investigators recommend including domestic violence and abuse as risk factors in public health strategies that target atopic disease assessments.

Outcomes in this new analysis were compared among children aged 6 to 11 years, all of whom had severe atopic dermatitis and were randomized to treatment with dupilumab or placebo for 16 weeks.

This newest analysis on atopic diseases compared outcomes between persons considered to be sexually diverse (lesbian, gay, or bisexual) and heterosexual individuals.

Despite the need for improved eczema therapies and a rapid increase in available clinical trials, participation remains low.

Melinda Gooderham, MD, MSc, FRCPC, Peterborough Regional Health Centre in Ontario, Canada, breaks down which subgroup of patients with atopic dermatitis (AD) may benefit the most from emerging therapies, as well as the advantages and disadvantages of these therapies.

Jonathan Silverberg, MD, PhD, MPH, George Washington University School of Medicine and Health Sciences, discusses results from a recent study for which he was the lead author.

Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses challenges many physicians face in getting approved for the most effective drugs to treat patients with atopic dermatitis (AD).